Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
EAS and AMR-altered non-Sq NSCLC showed lower rates of co-occurringandalterations relative to other ancestry groups. Ancestry-specific co-alterations included the co-occurrence ofandalterations in AMR,andalterations in SAS, and the mutual exclusivity ofandalterations in the EUR and AFR ancestries....
$阿斯利康(AZN)$$吉利德科学(GILD)$TROP2 ADC dato Dxd 2L+ non-sq NSCLC vs 多西他赛 ,OS 优势未达到统计学显著性,有临床意义。2L 多西确实不太容易打败。网页链接 下图是去年ESMO中期分析结果 我重新读了一下,看了一下wording,很可能non sq人群 HR上限是<1的,达到数值上的统计显著性。但由于预设的是全...
Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). J Clin Oncol. 2018;36(15_suppl):105. doi:10.1200/JCO.2018.36.15Google Scholar 37. Jotte R, Cap...
Companion diagnostic (CDx) testing for patients with advanced non‐small cell lung cancer (aNSCLC) identifies patients more likely to benefit from biomarker‐driven treatments. METHODS. Patients with nonsquamous cell (non‐Sq) aNSCLC from the Flatiron Health database (diagnosed January 1, 2011–...
6617Background: Nivo, a PD-1 antibody, received FDA approval based on superior overall survival in metastatic squamous (SQ) and non-squamous (NSQ) NSCLC patients who have progressed on or after platinum-based doublet chemotherapy. The pu... M Venkatachalam,M Venkatachalam,David D. Stenehjem,...
We aimed to evaluate the effect of hypofractionated post-operative radiotherapy on overall survival, disease-free survival (DFS), and local control rate in completely resected stage IA–IIIB non-small-cell lung cancer (NSCLC); to estimat... SD Trotsenko,VA Solodky,VM Sotnikov,... - 《Europea...
HANSIZHUANG was launched in March 2022 and has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC). Its marketing application of the...
Abbreviations Non-Sq NSCLC: Non-squamous non-small cell lung cancer; TPS: Tumour proportion score; PD-L1: Programmed cell death ligand 1; EGFR: Epidermal growth factor receptor; ALK: Anaplastic lymphoma kinase; ROS1: ROS proto- oncogene 1; BRAF: B-Raf proto-oncogene; TKIs: Tyrosine kinase ...
Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades, the management of non-small cell lung cancer (NSCLC) has undergone a significant revolution. Since the first identification of activating mutations in the epid